Safety Study of ALRN-6924 in Patients With Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome

NCT02909972 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

55

Enrollment

INDUSTRY

Sponsor class

Conditions

Acute Myeloid Leukemia
Myelodysplastic Syndromes

Interventions

DRUG: ALRN-6924
DRUG: ALRN-6924 in combination with cytarabine

Sponsor

Aileron Therapeutics, Inc.